Life Science News

lobe sciences ltd. (CSE: LOBE) (OTCQB: LOBED) ("Lobe" or the "Company"), a Canadian Biotechnology company committed to discovering and developing psychedelic derived medicines today announced it has developed its initial Phase 1 study plan intended to demonstrate the safety and appropriate dosing range for its proprietary new chemical entity; L-130. It is also announcing the acquisition of a second new chemical entity, L-131, which is expected to enter preclinical toxicity trials later this year or early in 2023.

Philip Young, CEO of Lobe Sciences stated, "L-130 and L-131 are unique synthetic analogues of psilocin, the active metabolite of natural psilocybin, a substance extracted from a species of psychedelic mushroom. We have designed a regulatory development strategy to support the registration of these new chemical entities with the U.S. Food and Drug Administration (FDA). Our initial focus for our clinical program is to treat neurologic disorders, such as severe anxiety and we are in the final stages of selecting a contract research organization to support these studies."

We expect to submit a Pre-IND meeting request with the FDA in the third quarter of this year. After receiving the FDA response to our Pre-IND questions, we will file our investigational new drug application (IND) to enable us to move forward with our initial clinical study later this year or early in 2023.

Our initial Phase 1 study will evaluate the safety of L-130 in healthy volunteers in a single ascending dose trial. Following this, a second Phase 1 trial will evaluate longer term use of the drug candidate in a multiple ascending dose study (MAD). Once an appropriate dosing level is determined to have no hallucinatory effect, we will conduct a third and final safety study in patients evaluating both pharmacokinetics and preliminary efficacy at the selected dose. This Phase Ib MAD trial will also seek to confirm the synergistic effects seen in preclinical studies when combinations with N-acetyl cysteine (NAC) were administered with a similar psychedelic compound. Lobe has filed a patent protecting the use of NAC in combination with various psychedelic derived compounds.

Lobe's approach is focused on providing a therapeutic that employs sub-psychedelic dose levels to treat patients at home or in their physician's office and avoiding long stays associated with other treatment modalities. Delivering a non-hallucinatory dose of L-130 over several days will enable patients and their doctors the opportunity to maintain their normal routine while receiving treatment.

L-131 will enter preclinical rodent studies in late 2022 or early 2023 to evaluate its safety and pharmacokinetics. The initial trial will be a standard 28-day preclinical safety study to enable human Phase 1 trials planned later in 2023.

About lobe sciences ltd.
Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

lobe sciences ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

This does not constitute an offer to sell or a solicitation of offers to buy any securities.

Disclaimer for Forward-Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, and the development of innovative devices and delivery mechanisms to improve mental health and wellness, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment;, that the Company's drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company's corporate goals and objectives; and other risk factors detailed in the Company's continuous disclosure filings from time to time, as available under the Company's profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/130261

News Provided by Newsfile via QuoteMedia

LOBE:CNX
Lobe Sciences

Lobe Sciences


Keep reading...Show less
Lobe Sciences Files Patent Application Covering the Preparation of Stable Psilocin Prodrugs and Analogues and their Uses Further Strengthening its Intellectual Property Portfolio

Lobe Sciences Files Patent Application Covering the Preparation of Stable Psilocin Prodrugs and Analogues and their Uses Further Strengthening its Intellectual Property Portfolio

lobe sciences ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has filed a provisional patent for the preparation and use of its proprietary and stable psilocin related compounds.

Philip Young, CEO of Lobe Sciences stated, "Our patent portfolio now consists of multiple patent filings for the use and delivery of psilocybin, psilocin analogues and N-Acetyl Cysteine (NAC) as well as a new patent that covers the uses and preparation of multiple proprietary stable forms of the psilocin molecule. The Company is actively pursuing drug development programs using two initial proprietary psilocin analogues. L-130, targeting neurologic conditions such as severe anxiety, Post Traumatic Stress Disorder (PTSD), as well as other brain traumas. L-131, a second new chemical entity related to psilocin and covered in the recently filed patent application is a drug candidate for a second neurological disorder affecting children."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Lobe Sciences Ltd. and Clearway Global LLC Enter into a Development Agreement to Manage Lobe Sciences Ltd.'s Global Regulatory and Development Strategy and its Implementation

Lobe Sciences Ltd. and Clearway Global LLC Enter into a Development Agreement to Manage Lobe Sciences Ltd.'s Global Regulatory and Development Strategy and its Implementation

lobe sciences ltd. (CSE: LOBE) (OTCQB: LOBED) ("Lobe" or the "Company"), a Canadian Biopsychedelics company committed to discovering and developing psychedelic inspired medicines for the improvement of neurologic, brain and mental health disorders, today announced an exclusive agreement with Clearway Global LLC ("Clearway").

Philip Young, CEO of Lobe stated, "We are pleased to have the opportunity to team up with the Clearway network and in particular with Dr. Fred Sancilio, a global expert in drug development and strategic planning. Dr. Sancilio brings over 40 years of pharmaceutical experience to our program and has a track record of success that is unmatched".

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Lobe Sciences Announces Roadmap for Remainder of 2022 and Early 2023

Lobe Sciences Announces Roadmap for Remainder of 2022 and Early 2023

lobe sciences ltd. (CSE: LOBE) (OTCQB: LOBED) ("Lobe" or the "Company"), a Canadian Biopharmaceutical Company committed to discovering and developing psychedelic inspired medicines for the improvement of neurologic, brain and mental health disorders is reporting its roadmap for the remainder of 2022 and into 2023.

Philip Young CEO and Director stated, "I am happy to report that we have made significant progress since our last update in Q3 last year. The next 12 months will see the culmination of investments we've made in the development of therapeutics to treat neurological diseases such as Post Traumatic Stress Disorder (PTSD) and mild Traumatic Brain Injury (mTBI). Preclinical models have shown statistically significant results in the treatment of PTSD and mTBI caused by induced trauma. The combinations of psilocybin with n-acetyl cysteine (NAC) delivered superior results compared to either drug alone. Our patent pending combination therapy may allow for the use of sub-psychedelic dosing while retaining efficacy on these and other disorders."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Lobe Sciences Ltd Announces Change in Record Date of Share Consolidation

Lobe Sciences Ltd Announces Change in Record Date of Share Consolidation

lobe sciences ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") announces that further to the Company's June 6, 2022, news release, the record date for the six for one consolidation has been adjusted to June 10, 2022.

The Canadian Securities Exchange has published a bulletin confirming that trading will remain halted June 9, 2022, and resume trading on a consolidated basis on Friday, June 10.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Lobe Sciences Announces Share Consolidation

Lobe Sciences Announces Share Consolidation

lobe sciences ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") announces that its board of directors has authorized the implementation of a consolidation (the "Consolidation") of the Company's common shares (the "Shares") on the basis of one (1) post-Consolidation Share for every six (6) pre-Consolidation Shares, which will become effective on June 9, 2022 (the "Effective Date"). Neither the Company's name, nor its trading symbols, will change as a result of the Consolidation.

The Company currently has 229,383,983 Shares issued and outstanding. Following the Consolidation, there will be approximately 38,230,000 Shares issued and outstanding. No fractional Shares will be issued, and any fraction of a Share will be rounded up to the nearest whole number of Shares. The Shares will trade on a post-Consolidation basis under the new CUSIP #53946V206 and ISIN #CA53946V2066. The Shares are expected to begin trading on a post-Consolidation basis on the Canadian Securities Exchange when markets open on the Effective Date.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

COMPASS Pathways plc announces second quarter 2022 financial results and business highlights

-

Highlights:
  • Kabir Nath appointed as Chief Executive Officer
  • Phase III program submitted to FDA and under review
  • COMP360 phase II study in anorexia nervosa launched
  • Cash position at 30 June 2022 of $207.2 million
  • Conference call today at 8:00am ET (1:00pm UK)

COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2022 and gave an update on recent progress across its business.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Morgan Stanley Positive in First Psychedelics Research Report

Morgan Stanley Positive in First Psychedelics Research Report

Morgan Stanley (NYSE:MS) has shared its first official commentary on the psychedelics industry.

The concept of investing in psychedelic medicine received a legitimate vote of confidence of sorts after the well-established banking firm released an introductory study evaluating the potential attached to the sector.

The research is intended to offer an initial look at the psychedelics investment proposal.

Keep reading...Show less

COMPASS Pathways Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635

COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that COMPASS granted a non-qualified share option to purchase an aggregate of 600,000 ordinary shares, nominal value £0.008 each, in the capital of the Company to Kabir Nath, COMPASS's newly appointed chief executive officer. In accordance with NASDAQ Listing Rule 5635(c)(4), the non-qualified share option award was approved by the Compensation and Leadership Development Committee of COMPASS's Board of Directors and made as a material inducement to Kabir's entry into employment with COMPASS as its new chief executive officer.

The non-qualified share option was granted on August 1, 2022 and has an exercise price per share equal to $14.94, the closing price of the Company's American Depositary Shares on the Nasdaq Global Select Market on the grant date. The non-qualified share option has a 10-year term and vests as to one-fourth on August 1, 2023 (the first anniversary of his employment commencement date) and as to the remaining three-fourths in equal monthly installments over the following 36 months, subject to Kabir remaining an employee of the Company on the applicable vesting dates. The non-qualified share option has other terms that mirror those of non-qualified share options granted under COMPASS's 2020 Share Option and Incentive Plan and COMPASS's standard form of non-qualified share option agreement.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

COMPASS Pathways to participate in upcoming BTIG Biotechnology Conference and Canaccord Annual Growth Conference

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in two upcoming events as follows:

  • BTIG Biotechnology Conference: host investor meetings on 9 August 2022
  • Canaccord Annual Growth Conference: presentation at 8:30 am ET on 10 August 2022 and host investor meetings

A live audio webcast of each event will be accessible from the "Events" page of the Investors section of the COMPASS website. Each replay of the webcast will be accessible for 30 days following each event. For more information, please visit ir.compasspathways.com.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa

Multi-centre, d ouble-blind randomised controlled phase II trial will investigate the efficacy of COMP360 psilocybin therap y in anorexia nervosa for which there is currently no approved pharmacological treatment option


News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Gwella Mushrooms CEO Peter Reitano

Gwella Mushrooms CEO Peter Reitano: Early Stage Traction, Revenue and a Great Path to Profitability

Gwella Mushrooms CEO Peter Reitano: Early Stage Traction, Revenue and a Great Path to Profitabilityyoutu.be

Keep reading...Show less

Latest Press Releases

Related News

×